The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer
Abstract
Purpose To develop a radiomics signature to estimate disease-free survival (DFS) in patients with early-stage (stage I–II) non–small cell lung cancer (NSCLC) and assess its incremental value to the traditional staging system and clinical-pathologic risk factors for individual DFS estimation. Materials and Methods Ethical approval by the institutional review board was obtained for this retrospective analysis, and the need to obtain informed consent was waived. This study consisted of 282 consecutive patients with stage IA–IIB NSCLC. A radiomics signature was generated by using the least absolute shrinkage and selection operator, or LASSO, Cox regression model. Association between the radiomics signature and DFS was explored. Further validation of the radiomics signature as an independent biomarker was performed by using multivariate Cox regression. A radiomics nomogram with the radiomics signature incorporated was constructed to demonstrate the incremental value of the radiomics signature to the traditional staging system and other clinical-pathologic risk factors for individualized DFS estimation, which was then assessed with respect to calibration, discrimination, reclassification, and clinical usefulness. Results The radiomics signature was significantly associated with DFS, independent of clinical-pathologic risk factors. Incorporating the radiomics signature into the radiomics-based nomogram resulted in better performance (P < .0001) for the estimation of DFS (C-index: 0.72; 95% confidence interval [CI]: 0.71, 0.73) than with the clinical-pathologic nomogram (C-index: 0.691; 95% CI: 0.68, 0.70), as well as a better calibration and improved accuracy of the classification of survival outcomes (net reclassification improvement: 0.182; 95% CI: 0.02, 0.31; P = .02). Decision curve analysis demonstrated that in terms of clinical usefulness, the radiomics nomogram outperformed the traditional staging system and the clinical-pathologic nomogram. Conclusion The radiomics signature is an independent biomarker for the estimation of DFS in patients with early-stage NSCLC. Combination of the radiomics signature, traditional staging system, and other clinical-pathologic risk factors performed better for individualized DFS estimation in patients with early-stage NSCLC, which might enable a step forward precise medicine. © RSNA, 2016 Online supplemental material is available for this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrell (2015) · Springer Series in Statistics · doi:10.1007/978-3-319-19425-7 · Cited by 6,878
Decision curve analysis: a novel method for evaluating prediction models
Vickers, A. J., & Elkin, E. B. (2006) · Medical Decision Making · doi:10.1177/0272989x06295361 · Cited by 6,341
Radiomics: extracting more information from medical images using advanced feature analysis
Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R. G. P. M., Granton, P., Zegers, C. M. L., Gillies, R., Boellard, R., Dekker, A., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.036 · Cited by 6,084
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Pencina, M. J., D'Agostino, R. B., & Steyerberg, E. W. (2011) · Statistics in Medicine · doi:10.1002/sim.4085 · Cited by 2,453
Radiomics: the process and the challenges
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
Moons, K. G. M., Kengne, A. P., Woodward, M., Royston, P., Vergouwe, Y., Altman, D. G., & Grobbee, D. E. (2012) · Heart · doi:10.1136/heartjnl-2011-301246 · Cited by 889
Concordance probability and discriminatory power in proportional hazards regression
Gönen, M., & Heller, G. (2005) · Biometrika · doi:10.1093/biomet/92.4.965 · Cited by 673
Liang, W., Zhang, L., Jiang, G., Wang, Q., Liu, L., Liu, D., Wang, Z., Zhu, Z., Deng, Q., Xiong, X., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.6661 · Cited by 649
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Gui, J., & Li, H. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti422 · Cited by 551
Zhang, J.-X., Song, W., Chen, Z.-H., Wei, J.-H., Liao, Y.-J., Lei, J., Hu, M., Chen, G.-Z., Liao, B., Lu, J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70491-1 · Cited by 544
Crinò, L., Weder, W., van Meerbeeck, J., & Felip, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq207 · Cited by 539
Treatment of Non-small Cell Lung Cancer Stage I and Stage II
Scott, W. J., Howington, J., Feigenberg, S., Movsas, B., & Pisters, K. (2007) · Chest · doi:10.1378/chest.07-1378 · Cited by 520
Ganeshan, B., Panayiotou, E., Burnand, K., Dizdarevic, S., & Miles, K. (2012) · European Radiology · doi:10.1007/s00330-011-2319-8 · Cited by 505
Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J. Y., Faivre-Finn, C., Lim, E., Rocco, G., Senan, S., Van Schil, P., Veronesi, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu089 · Cited by 493
Halabi, S., Lin, C.-Y., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 478
Chansky, K., Sculier, J.-P., Crowley, J. J., Giroux, D., Van Meerbeeck, J., & Goldstraw, P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a7716e · Cited by 456
The revised TNM staging system for lung cancer.
Rami–Porta, R., Crowley, J. J., & Goldstraw, P. G. (2009) · PubMed · Cited by 442
Radiogenomics: Creating a link between molecular diagnostics and diagnostic imaging
Rutman, A. M., & Kuo, M. D. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.01.050 · Cited by 321
Judging New Markers by Their Ability to Improve Predictive Accuracy
Kattan, M. W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.634 · Cited by 265
Mauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Kuo, M. D., & Jamshidi, N. (2014) · Radiology · doi:10.1148/radiol.13132195 · Cited by 239
Win, T., Miles, K. A., Janes, S. M., Ganeshan, B., Shastry, M., Endozo, R., Meagher, M., Shortman, R. I., Wan, S., Kayani, I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1307 · Cited by 203
Hayward, R. A., Kent, D. M., Vijan, S., & Hofer, T. P. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-18 · Cited by 196
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel-Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P., Onetto, N., Stein, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
Kuo, M. D., Gollub, J., Sirlin, C. B., Ooi, C., & Chen, X. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.04.031 · Cited by 168
Self-citationGeneration of a Concise Gene Panel for Outcome Prediction in Urinary Bladder Cancer
Mitra, A. P., Pagliarulo, V., Yang, D., Waldman, F. M., Datar, R. H., Skinner, D. G., Groshen, S. G., & Côté, R. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5744 · Cited by 107
Molecular markers for bladder cancer: the road to a multimarker approach
Birkhahn, M., Mitra, A. P., & Côté, R. J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.12.1717 · Cited by 85
Avoidable cancer deaths globally
Brawley, O. W. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20108 · Cited by 59
Mitra, A. P., Lam, L. L. C., Ghadessi, M., Erho, N., Vergara, I. A., Alshalalfa, M., Buerki, C., Haddad, Z., Sierocinski, T., Triche, T. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju290 · Cited by 53
Altazi, B. A., Fernandez, D. C., Zhang, G., Biagioli, M. C., Moros, E. G., & Moffitt, H. L. (2015) · Medical Physics · doi:10.1118/1.4924344 · Cited by 11
Tibshirani (1997) · doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
Cited by
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Liu, Z., Wang, S., Dong, D., Wei, J., Fang, C., Zhou, X., Sun, K., Li, L., Li, B., Wang, M., et al. (2019) · Theranostics · doi:10.7150/thno.30309 · Cited by 967
Self-citationPredicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Xu, X., Zhang, H.-L., Liu, Q.-P., Sun, S.-W., Zhang, J., Zhu, F.-P., Yang, G., Yan, X., Zhang, Y.-D., & Liu, X.-S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.023 · Cited by 706
A deep learning-based radiomics model for prediction of survival in glioblastoma multiforme
Lao, J., Chen, Y., Li, Z.-C., Li, Q., Zhang, J., Liu, J., & Zhai, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10649-8 · Cited by 630
Metadata
- Authors
- Huang, Y., Liu, Z., He, L., Chen, X., Pan, D., Ma, Z., Liang, C., Tian, J., & Liang, C.
- Venue
- Radiology
- Published
- 2016-12
- Volume
- 281
- Issue
- 3
- Pages
- 947-957
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2461805626
- Cited by
- 743
- References
- 37
- FWCI
- 50.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.